The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease

Current Molecular Medicine

Volumn 11, Issue 6, 2011, Pages 453-464

  Rull, A ^a   Garcia R ^b   Fernandez Sender L ^a   Beltran Debon R ^a   Aragones G ^a   Alegret, J M ^c   Alonso Villaverde, C ^d   Mackness, B ^a   Mackness, M ^a   Camps, J ^a   Martin Paredero, V ^b   Joven, J ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Atherosclerosis; CCL2; Inflammation; Lactonase; Monocyte chemoattractant protein 1; Paraoxonase 1; Peripheral vascular disease; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCL2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION;

EID: 79960297734     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411796268713     Document Type: Article

References (43)

1. Criqui MH. Peripheral arterial disease-epidemiological aspects. Vasc Med 2001; 6: 3-7.
2. Mehlsen J, Wiinberg N, Joergensen BS, Schultz-Larsen P. High prevalence of peripheral arterial disease in patients with previous cerebrovascular or coronary event. Blood Press 2010; 19: 308-312.
3. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004; 292: 453-461.
4. Gornik HL, Creager MA. Contemporary management of peripheral arterial disease: Cardiovascular risk-factor modification. Cleve Clin J Med 2006; 73 Suppl4: S30-S37.
5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
6. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386
7. Murabito JM, Keyes MJ, Guo CY, et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study. Atherosclerosis 2009; 203: 509-514.
8. Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol 2010; 55: 2017-2023.
9. McDermott MM, Lloyd-Jones DM. The role of biomarkers and genetics in peripheral arterial disease. J Am Coll Cardiol 2009; 54: 1228-37.
10. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322.
11. Feldmann M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest 2008; 118: 3533-3536.
12. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-866.
13. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004; 318: 680-683.
14. Rodríguez-Sanabria F, Rull A, Beltrán-Debón R, et al. Tissue distribution and expression of paraoxonases and chemokines in mouse: The ubiquitous and joint localisations suggest a systemic and coordinated role. J Mol Histol 2010; 41: 379-386.
15. Rull A, Camps J, Alonso-Villaverde C, Joven J. Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. Mediators Inflamm 2010; 2010. pii: 326580.
16. Petrkova J, Szotkowska J, Hermanova Z, Lukl J, Petrek M. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Mediators Inflamm 2004; 13: 39-43.
17. van Wijk DF, van Leuven SI, Sandhu MS, et al. Chemokine Ligand 2 Genetic Variants, Serum Monocyte Chemoattractant Protein-1 Levels, and the Risk of Coronary Artery Disease. Arterioscler Thromb Biol 2010; 30: 1460-1466.
18. Marsillach J, Aragonès G, Beltrán R, et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009; 42: 91-98.
19. Ferré N, Marsillach J, Camps J, et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006; 45: 51-59.
20. Pasqualini L, Cortese C, Marchesi S, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183: 349-354.
21. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46: 83-106.
22. Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
23. Yun WS, Rho YN, Park UJ, Lee KB, Kim DI, Kim YW. Prevalence of asymptomatic critical carotid artery stenosis in Korean patients with chronic atherosclerotic lower extremity ischemia: is a screening carotid duplex ultrasonography worthwhile? J Korean Med Sci 2010; 25: 1167-1170.
24. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300: 197-208.
25. Marsillach J, Camps J, Beltran-Debón R, et al. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin Invest 2011; 41: 308-314.
26. Alonso-Villaverde C, Aragonés G, Beltrán-Debón R, et al. Host-Pathogen Interactions in the Development of Metabolic Disturbances and Atherosclerosis in HIV Infection: The Role of CCL2 Genetic Variants. Cytokine 2010; 51: 251-258.
27. Parra S, Marsillach J, Aragonés G, et al. Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis 2010; 201: 627-623.
28. Dean AG, Sullivan KM, Soe MM. Open Epi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. www.OpenEpi.com
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
30. Fung ET, Wilson AM, Zhang F, et al. A biomarker panel for peripheral arterial disease. Vasc Med 2008; 13: 217-224.
31. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
32. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
33. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843
34. Wilson AM, Kimura E, Harada RK, et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007; 116: 1396-4103.
35. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004; 110: 2204-2209.
36. Hoogeveen RC, Morrison A, Boerwinkle E, et al. Plasma MCP-1 levels and risk for peripheral arterial disease and incident coronary Heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301-307.
37. Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104: 2395-2400.
38. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004; 36: 405-410.
39. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
40. Schnabel RB, Baumert J, Barbalic M, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood. 2010; 115: 5289-5299.
41. Parra S, Marsillach J, Aragonés G, et al. Methodological constrains in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. Lipids Health Dis 2010; 9: 32.
42. Knowles JW, Assimes TL, Li J, Quetermous T, Cooke JP. Genetic susceptibility to peripherial arterial disease: A dark corner in vascular biology. Arterioscler Thromb Vasc Biol 2007; 27: 2068-2078.
43. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 1233-1238.